Study on the progression types of cancer in patients with breast cancer undergoing eribulin chemotherapy and tumor microenvironment
Authors:
- Shinichiro KashiwagiShinichiro Kashiwagi
- Gen TsujioGTGen Tsujio
- Yuka AsanoYAYuka Asano
- Wataru GotoWGWataru Goto
- Koji TakadaKTKoji Takada
- Katsuyuki TakahashiKTKatsuyuki Takahashi
- Tamami MorisakiTMTamami Morisaki
- Hisakazu FujitaHFHisakazu Fujita
- Tsutomu TakashimaTTTsutomu Takashima
- Shuhei TomitaSTShuhei Tomita
- Masahiko OhsawaMOMasahiko Ohsawa
- Kosei HirakawaKHKosei Hirakawa
Open Access
- 9 March 2018
- journal article
- research article
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 16 (1) , 1-9
Abstract
Recently, the concepts of progression due to pre-existing lesions (PPL) and progression due to new metastasis (PNM) have been proposed to differentiate the progression types of treatment-resistant cancers. Previously, the differences between these two progression types did not affect the determination of treatment strategies since both PPL and PNM are classified as progressive disease based on the response evaluation criteria in solid tumors (RECIST) diagnostic criteria. On the other hand, tumor infiltrating lymphocytes (TILs) are effective when used as indicators for monitoring the immune tumor microenvironment (iTME) in the cancer host, and TILs play an important role as biomarkers in predicting prognosis and therapeutic effects. This study focused on the progression types of cancer in patients undergoing eribulin chemotherapy. In addition, the iTME in individuals with PPL and PNM was evaluated using TILs as a marker. Of the 52 patients with locally advanced or metastatic breast cancer who underwent chemotherapy with eribulin, 40 remained in the study, and 12 patients were dropout cases. The antitumor effect was evaluated based on the RECIST criteria using version 1.1. TILs were defined as the infiltrating lymphocytes within tumor stroma and were expressed in proportion to the field investigated. In PPL cases, the high-TIL group was considered as type I and the low-TIL group was classified as type II. In PNM cases, the high-TIL group was considered as type III and the low-TIL group was classified as type IV. In 19 cases, individuals with type I progression had significantly longer progression free survival and overall survival (OS) compared to those with type III progression (p = 0.040, p < 0.001, log-rank). Individuals with type I progression had significantly prolonged survival post progression compared to those with type II progression (p = 0.048, log-rank). A multivariate analysis that validate the effect of OS showed that these were independent factors of good prognosis (p = 0.003; hazard ratio [HR] = 0.065) (p = 0.006; HR = 0.105). The effects of eribulin chemotherapy suggested that patients with progressive-type breast cancer that proliferates in a good iTME may have a good prognosis.Keywords
Funding Information
- Japan Society for the Promotion of Science (25461992, 26461957, 17K10559)
This publication has 30 references indexed in Scilit:
- “New” metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapyBreast Cancer Research, 2015
- Crosstalk between CTC, Immune System and Hypoxic Tumor MicroenvironmentCancer Microenvironment, 2014
- Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer modelsCancer Science, 2014
- The components of progression as explanatory variables for overall survival in the Response Evaluation Criteria in Solid Tumours 1.1 databaseEuropean Journal of Cancer, 2014
- Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial–mesenchymal transition (EMT) to mesenchymal–epithelial transition (MET) statesBritish Journal of Cancer, 2014
- Cancer Immunotherapy2013
- The immune contexture in human tumours: impact on clinical outcomeNature Reviews Cancer, 2012
- Immune parameters affecting the efficacy of chemotherapeutic regimensNature Reviews Clinical Oncology, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009